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Abstract
The mode of action of the anti-fungal compounds, 1,10-phenanthroline (phen), [Cu(phen)2(mal)] · 2H2O,
[Mn(phen)2(mal)] · 2H2O and [Ag2(phen)3(mal)] · 2H2O (malH2 = malonic acid), was examined using the patho-
genic yeast Candida albicans. The compounds have minimum inhibitory concentrations (MIC’s) in the range
1.25–5.0 μg cm−3 and at a concentration of 10 μg cm−3 display some fungicidal activity. Yeast cells exposed to
these drugs show a diminished ability to reduce 2,3,5-triphenyltetrazolium chloride (TTC), indicating a reduction
in respiratory function. Treating exponential and stationary phase yeast cells with phen and the Cu(II) and Mn(II)
complexes causes a dramatic increase in oxygen consumption. All of the drugs promote reductions in the levels of
cytochromes b and c in the cells, whilst the Ag(I) complex also lowers the amount of cytochrome aa3. Cells treated
with phen and the Cu(II) and Ag(I) species show reduced levels of ergosterol whilst the Mn(II) complex induces an
increase in the sterol concentration. The general conclusion is that the drugs damage mitochondrial function and
uncouple respiration. That the drugs are not uniformly active suggests their bioactivity has a degree of metal-ion
dependency. Phen and metal-phen complexes represent a novel set of highly active anti-fungal agents whose mode
of action is significantly different to that of the polyene and azole prescription drugs.
Introduction
Candida albicans is an opportunistic fungal pathogen
capable of causing a range of superficial and sys-
temic infections in the immuno-compromised host.
The increasing incidence of fungal infections due to
the advent of AIDS and immunosuppressive therapies
has greatly stimulated the interest in the development
of new anti-mycotic drugs for the treatment of infec-
tions caused by C. albicans and other Candida species
(Pfaller et al. 1998; Denning et al. 1997; Lunel et al.
1999). In our laboratories we have synthesized an ar-
ray of transition metal complexes and screened them
for their ability to inhibit the growth of clinical iso-
lates of C. albicans (Geraghty et al. 1999a, b, c;
Devereux et al. 2000a, b; McCann et al. 2000), Can-
dida glabrata, Candida tropicalis and Candida krusei
(Geraghty et al. 2000) in RPMI medium at 37 ◦C.
1,10-Phenanthroline (phen) and a number of transition
metal complexes incorporating this chelating ligand
were found to be extremely active, in vitro, at 37 ◦C.
Our recent efforts have focused on the mechanisms of
the antimycotic effects and it has been shown that the
potent copper(II) complex, [Cu(phen)2(mal)] · 2H2O
(malH2 = malonic acid), induces significant cellu-
lar oxidative stress decreased reduced:oxidized glu-
tathione ratios (GSH:GSSG) and increased levels of
lipid peroxides (McCann et al. 2000).
Existing therapies for systemic fungal infections
rely upon the use of polyene and azole anti-fungal
drugs. Resistance to these agents has been reported
(Odds 1996; Klepser et al. 1997) and this reduces
the efficacy of therapy and can ultimately lead to the
death of the patient. Mechanisms that confer anti-
fungal drug resistance in yeast include an increase in
the expression of drug efflux pumps which remove the
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drug from the cell before a toxic concentration can be
reached (Wirsching et al. 2000; Moran et al. 1998),
alterations in the target of the drug and variations
in the ergosterol biosynthetic pathway (Odds 1996).
Due to their different mode of anti-fungal activity
metal-based drugsmay represent a novel group of anti-
fungal agents which may have potential applications
either alone or in combination with existing agents
and which may circumvent resistance to conventional
drugs.
The present in vitro investigation concentrates on
establishing the effects of phen and a selection of
metal-phen complexes on the viability, mitochondr-
ial function and cytochrome and ergosterol levels of
C. albicans with a view to establishing their primary
mode of action. The metal complexes chosen for the
study all have the same ligands (phen and mal2−)
and differ only in the nature of the transition metal
{Cu(II), Mn(II), Ag(I)}. This will allow conclusions
to be drawn regarding how the mode of action of the
complex is influenced by the nature of the metal ion.
Although metal-free phen will also be administered
to the cells it is assumed that this powerful chelating
ligand will sequester a transition metal ion from either
the medium or the cell and that any bioactivity is really
attributable to the resultant metal-phen complex.
Methods and materials
Chemicals
Chemicals and growth media were obtained from
commercial sources and used without further purifi-
cation. [Cu(phen)2(mal)] · 2H2O, [Mn(phen)2(mal)]
· 2H2O, [Ag2(phen)3(mal)] · 2H2O and [Mn(phen)2
(CH3CO2)2] · 4H2O were prepared as previously de-
scribed (McCann et al. 2000).
Yeast isolate and culture conditions
C. albicans ATCC 10231 was obtained from the
American Type Culture Collection (Manasas, VA,
USA). Cultures were grown on Sabouraud dextrose
agar (SDA) plates at 37 ◦C and maintained at 4 ◦C
for short-term storage. Cultures were routinely sub-
cultured every 4-6 weeks. Cultures were grown to the
stationary phase at 30 ◦C and 200 rpm in minimal
medium (MM) (2% w/v agar, 2% w/v glucose, 0.5%
w/v yeast nitrogen base (without amino acids or am-
monium sulphate), 0.5% w/v ammonium sulphate).
For media containing glycerol as the carbon source
2% w/v glycerol was substituted for the glucose in the
above formulation. Media were sterilised by autoclav-
ing at 121 ◦C and 100 kPa for 15 min. Alternatively,
solutions that were susceptible to decomposition dur-
ing autoclaving were sterilized by membrane filtration
using 0.45 μm Millipore membrane filters.
Minimum inhibitory concentrations (MIC’s)
RPMI-1640 broth medium was used for the anti-
Candida Susceptibility testing. RPMI (5.15 g) was
dissolved in cold distilled water (425 cm3) in a 1L
Duran bottle and the pH adjusted to 4.0 using a few
drops of HCl (ca. 2 M). The resulting solution was
autoclaved and then allowed to cool to approx. 50 ◦C.
Morpholinepropanesulfonic acid (MOPS) (17.3 g) and
L-glutamate (0.15 g) were dissolved together with
stirring in distilled water (50 cm3) and the resulting
solution filter sterilized. The MOPS and L-glutamate
solution was added to the warm RPMI and the pH of
the mixture adjusted to 7.0 using sterile NaOH (6 M).
Prior to MIC testing, cells were grown on SDA at
37 ◦C for 24 h. Cell suspensions were prepared in ster-
ile phosphate buffered saline (PBS, pH 7.2) and cells
were counted microscopically following dilution with
PBS. A microtitre plate was inoculated with cells at
a density of 5 × 105 cells cm−3. Solutions of the test
drugs were prepared by dissolving the solid (0.02 g)
in distilled water (10 cm3) to yield a stock solution
of concentration 2000 μg cm−3. Doubling dilutions
of these stock solutions were made to yield a series
of test solutions ranging in concentrations from 20–
1.25 μg cm−3. The drug/cell mixtures were incubated
at 37 ◦C for 24 h with continuous shaking and the
assays were performed in triplicate. Plates were read
using a Labsystems iEMS Reader MF (absorbance at
λ = 540 nm) and data were statistically analysed.
Yeast cell viability
Yeast cells were grown in the presence of drug
(10 μg cm−3) to the late exponential phase (18–24 h)
in MM at 30 ◦C in an orbital incubator. Through serial
dilution, 2.5 × 103 cells cm−3 were obtained and re-
suspended in sterile PBS. From this culture 0.1 cm3
was spread-plated onto SDA plates resulting in a final
cell number of 250 per plate. Cells were incubated at
30 ◦C for 48 h and the number of colonies was ascer-
tained and expressed as a percentage with respect to
the control (100%).
Colonies were overlaid with molten agar (2%
w/v agar, 0.5% w/v glucose) containing 2,3,5-
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triphenyltetrazolium chloride (TTC, 0.05% w/v) and
incubated at 30 ◦C for 2 h. Respiring colonies reduce
TTC to a dark red colour while those with reduced
respiratory function are unable to do this and remain
white. Non-respiring (white) colonies were plated on
MM containing either glucose or glycerol as the car-
bon source and then incubated at 30 ◦C for 48 h.
The resulting colonies were counted and expressed
as a percentage with respect to the control (100%).
These colonies were overlaid once again with TTC,
incubated and any colour changes noted.
Differential spectra of yeast cytochromes
Two separate experiments were conducted at 30 ◦C
in MM in an orbital incubator using a drug concen-
tration of 10 μg cm−3. Firstly, drugs were added
to yeast cells (cell density 1 × 105 cells cm−3) in
the lag/early exponential phase and incubated for 18–
24 h. Cells were then harvested by centrifugation at
2100 × g for 5 min, washed three times with PBS
(pH 7.2). Half of the sample (for oxidation) was re-
suspended in 0.2% w/v sodium hypochlorite solution
(5 cm3). The cells were centrifuged and re-suspended
in 50% v/v glycerol (10 cm3). The other half of the
sample (for reduction) was prepared by re-suspending
cells in 50% v/v glycerol and adding a few crystals of
sodium dithionite. The reduced-oxidised cytochrome
difference spectrum (500–650 nm) was immediately
measured using a Cary Win-UV Spectrophotometer.
In the second series of experiments cells were grown
to stationary phase (24 h) with approximate cell den-
sity 2 × 108 cells cm−3. Drug was added and the
mixture incubated for a further 24 h and the cells then
harvested and treated as described above.
Respiratory measurements
Two separate experiments were conducted at 30 ◦C in
MM in an orbital incubator (200 rpm) using a drug
concentration of 10 μg cm−3. Firstly, drugs were
added to yeast cells (cell density of 1×105 cells cm−3)
in the lag/early exponential phase and incubated for
18–24 h. Cells were then harvested by centrifugation
at 2100 × g for 5 min, washed with PBS and re-
suspended in 0.05 M phosphate buffer (pH 7.2). In
the second series of experiments cells were grown to
stationary phase (24 h) with approximate cell density
2 × 108 cells cm−3. Drug was added and the mix-
ture incubated for a further 24 h and the cells then
harvested as described above. Oxygen-uptake mea-
surements were recorded using a Clark-type oxygen
electrode at 30 ◦C. Cells (1 × 108) were introduced
into the electrode chamber and the base respiration
rate measured. Oxygen-uptake rates were calculated
as μmol of O2 consumed/30 sec /1 × 108 cells.
Ergosterol extraction and analysis
Ergosterol was extracted from yeast cells using the
method of Arthington-Skaggs et al. 1999. Drug (con-
centration 10 μg cm−3) was added to lag/early expo-
nential phase cells (density 1×105 cells cm−3) in MM
and these were grown in an orbital incubator (200 rpm)
for 24 h at 30 ◦C. The resulting cells were harvested
by centrifugation, washed twice with PBS and re-
suspended in a liquid comprising 20% w/w aqueous
KOH and 60% v/v ethanol to give a final cell density
of 1×109 cells cm−3. The cells were placed in a water
bath at 90 ◦C for 1 h. Heptane (3 cm3) was added
and the mixture vortexed for 2 min. The upper heptane
layer containing the ergosterol was removed and dried
over anhydrous Na2SO4. The sample was analysed
using a Hewlett Packard 5890 Series II Gas Chromato-
graph (column: Chrompack WCOT fused silica; 25 m
length; 0.25 mm diameter).
Results
MIC values for the drugs against C. albicans in RPMI
medium at 37 ◦C are shown in Table 1. Metal-free
phen had an MIC value in the range 1.25–2.5μg cm−3
whereas the metal-phen complexes displayed slightly
higher values (2.5–5.0μg cm−3). Cell viability studies
carried out in MM at 30 ◦C (Table 2) indicate that at a
concentration of 10 μg cm−3 all of the complexes dis-
played some fungicidal activity. Growth curves for the
control and the drug-treated cells (using sub-MIC drug
concentrations) show that treatment of C. albicans
with the metal-phen complexes causes an extended lag
phase (Figure 1). Such a phenomenon has previously
been reported for C. albicans grown under oxygen
radical stressed conditions (Hye-Jin et al. 1999).
In the viability experiments the colonies that de-
veloped following the growth of cells in medium
supplemented with phen or metal phen complexes
were overlaid with agar containing TTC in or-
der to establish their respiratory status (Table 2).
All of the colonies growing on the control plates
reduced the dye to a red colour. However, af-
ter 24 h exposure to [Mn(phen)2(mal)] · 2H2O and
[Ag2(phen)3(mal)] · 2H2O the resulting colonies pro-
duced a pink colour with TTC, indicating a diminution
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Table 1. Growth of C. albicans in different concentrations of complexes in RPMI at 37 ◦C.
Growth
20 μg cm−3 10 μg cm−3 5 μg cm−3 2.5 μg cm−3 1.25 μg cm−3 0 μg cm−3
phen 2% 3% 5% 11% 92% 100%
[Cu(phen)2(mal)] · 2H2O 2% 4% 5% 78% 90% 100%
[Mn(phen)2(mal)] · 2H2O 3% 5% 5% 78% 84% 100%
[Ag2(phen)3(mal)] · 2H2O 4% 4% 5% 80% 98% 100%
Table 2. Cell viability studies in MM at 30 ◦C and effects on TTC.
Viability TTC Viability TTC
Growth time (h) 24 48
Control 100% red 100% red
phen 74% red 69% white
[Cu(phen)2(mal)] · 2H2O 78% red 70% white
[Mn(phen)2(mal)] · 2H2O 62% pink 58% white
[Ag2(phen)3(mal)] · 2H2O 80% pink 65% white
Fig. 1. Growth curves (absorbance at λ = 540 nm) for the con-
trol and the drug-treated cells RPMI over a 24 h period at 37 ◦C
(sub-MIC drug concentrations: phen = 1.25 μg cm−3; others
2.5 μg cm−3). Control, phen −, [Cu(phen)2(mal)] · 2H2 ,
[Mn(phen)2(mal)] · 2H2O•, [Ag2(phen)3(mal)] · 2H2O −.
in respiratory function. After 48 h only the control
colonies were capable of reducing TTC to a red colour,
indicating that cells treated with either phen or a metal-
phen complex experienced a significant reduction in
respiratory function. Further growth tests on the con-
trols and on colonies that were unable to reduce TTC
revealed that whereas all of the colonies were able to
grow on glucose as a carbon source many were inca-
pable of growing on glycerol (Table 3). The inability
to metabolise a non-fermentable carbon source such
Fig. 2. Respiration rates for control and drug-treated cells in MM
at 30 ◦C (drug concentration 10 μg cm−3). Drugs were added to
cells in the lag phase and the mixture incubated until they reached
the late exponential growth phase. At this stage the respiration rate
was recorded.
as glycerol is again a characteristic of respiratory de-
ficient cells. These results indicate that exposure to
either phen or a metal-phen complex creates a sig-
nificant number of respiratory-deficient cells in the
population and illustrates that these drugs interfere
with mitochondrial function (Reeves et al. 1991).
Respiration rates
Two different oxygen-uptake experiments were car-
ried out on the cells using drug concentrations of
10 μg cm−3. Firstly, drug was added to cells in
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Table 3. Viability of control and drug-treated cells at 30 ◦C in either glucose or glycerol
as a carbon source (drug concentration 10 μg cm−3).
TTC Viability in glucose Viability in glycerol
Control red 100% 93%
phen white 100% 56%
[Cu(phen)2(mal)] · 2H2O white 100% 56%
[Mn(phen)2(mal)] · 2H2O white 100% 43%
[Ag2(phen)3(mal)] · 2H2O white 100% 43%
Fig. 3. Respiration rates for control and drug-treated cells in MM
at 30 ◦C (drug concentration 10 μg cm−3). Cells were grown
to stationary phase and drug was then administered. Respiration
rates were recorded at time intervals of 2, 5 and 24 h following
the addition of drug. Control, phen•, [Cu(phen)2(mal)] · 2H2O,
[Mn(phen)2(mal)] · 2H2O, [Ag2(phen)3(mal)] · 2H2O −.
the lag phase and the mixture incubated until they
reached the late exponential phase, after which time
the respiration rate was recorded. Cells treated with
[Ag2(phen)3(mal)] · 2H2O at the lag phase had a lower
oxygen-uptake rate than the control (Figure 2). In con-
trast, cells exposed to phen, [Cu(phen)2(mal)] · 2H2O
and [Mn(phen)2(mal)] · 2H2O all showed higher up-
take rates than the control, with phen producing the
largest increase.
In the second series of experiments cells were
grown to stationary phase and then drug was admin-
istered. Oxygen-uptake measurements were made at
time intervals of 2, 5 and 24 h following the addition of
drug (Figure 3). In comparison to the control again it
was only the Ag(I) complex which prompted a reduc-
tion in oxygen-uptake over the 24 h period. All of the
other drugs caused an increase in gas uptake over the
first 5 h after administration compared to the control
cells. However, whereas the control showed a slight in-
crease in the uptake rate over the next 5–24 h time pe-
riod all of the drug-treated systems had a net decrease
in respiration rate over that period. Thus, with the ex-
ception of [Ag2(phen)3(mal)] · 2H2O, addition of drug
to cells which are either in the lag/exponential or the
stationary growth phase enhances oxygen-uptake by
the cells.
Cytochrome analysis
The interaction of the complexes with cytochromes
aa3, b and c was monitored by differential ab-
sorption spectroscopy and results obtained using the
lag/exponential phase C. albicans cultures are shown
in (Figure 4). Whilst cells grown in the presence of
the Cu(II) and Mn(II) complexes did show reduced
cytochrome levels, particularly cytochrome aa3, the
effect on the actively respiring cells was most pro-
nounced with the Ag(I) complex and metal-free phen.
These latter drugs appear to have almost completely
obliterated the cytochromes over the 24 h growth cy-
cle. In contrast, when cells that have been allowed
to grow for 24 h to stationary phase in a drug-free
environment were subsequently exposed to drug for
a period of 24 h no alteration in cytochrome profile
occurred.
Ergosterol content
The relative ergosterol content of drug-treated and
control cells was determined (Figure 5). C. albi-
cans cells exposed to phen, [Cu(phen)2(mal)] · 2H2O
and [Ag2(phen)3(mal)] · 2H2O showed diminished
levels of ergosterol, with the Cu(II) complex in-
flicting the most deleterious effect. As sterol syn-
thesis is dependent upon a fully functional cel-
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Fig. 4. Differential absorption spectra arising from the interaction of phen and the metal-phen complexes with cytochromes aa3 (λmax
600–604 nm), b (λmax 562–566 nm) and c (λmax 550–554 nm). Drugs were added to lag/exponential phase cultures of C. albicans.
Fig. 5. Relative ergosterol contents of drug-treated and control cells
(100%).
lular respiratory system the decrease in ergos-
terol levels observed with these drugs indicate a
disabled mitochondria. In contrast, cells treated
with [Mn(phen)2(mal)] · 2H2O showed an increase of
>50% in ergosterol content compared to the control.
Furthermore, tests carried out using the related Mn(II)
complex, [Mn(phen)2(CH3CO2)2] · 4H2O, showed
that this drug also prompted a similar increase in the
level of ergosterol (57% increase).
Discussion
In RPMI at 37 ◦C metal-free phen, [Cu(phen)2(mal)]
· 2H2O, [Mn(phen)2(mal)] · 2H2O and [Ag2(phen)3
(mal)] · 2H2O have a fungistatic effect on C. albicans
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(ATCC 10231) and MIC values were in the range 2.5–
5 μg cm−3. Introducing phen and metal-phen drugs
at a concentration of 10 μg cm−3 into lag phase cul-
tures in MM at 30 ◦C slightly reduced cell viability. In
addition, the resulting drug-treated cells were respira-
tory deficient (incapable of reducing TTC), indicating
damage to the mitochondria. In many cases, these res-
piratory deficient cells were also unable to grow on
glycerol as a carbon source, again demonstrating a
loss of mitochondrial function. Previous kinetic stud-
ies (McCann et al. 2000), in which a clinical isolate of
C. albicans was exposed to [Mn(phen)2(mal)] · 2H2O,
showed that the cells have to be metabolically ac-
tive before the administered metal complex has an
inhibitory effect. It has already been established (Ger-
aghty et al. 2000) that, in general, simple salts such as
MnCl2 · 4H2O and CuCl2 · 2H2O, have limited activity
against clinical isolates of C. albicans, indicating the
importance of the bidentate phen ligand in promoting
the anti-fungal effect of the metals.
An examination of the oxygen-uptake capabilities
of cells cultured in the presence of the drugs revealed
that, with the exception of the Ag(I) complex, there
was a significant increase in gas uptake. This result
indicates that although cells treated with phen and the
Cu(II) and Mn(II) complexes are incapable of reduc-
ing TTC (respiratory deficient) and are unable to grow
on glycerol they still display a marked ability to absorb
oxygen. This apparent contradiction may be explained
by the fact that cells are probably using the oxygen for
a process other than respiration (e.g. generation of free
radicals). Indeed, experiments using a clinical strain
of C. albicans treated with [Cu(phen)2(mal)] · 2H2O
(in RPMI at 37 ◦C) revealed that the complex caused
significant cellular oxidative stress (decreased ratio of
GSH:GSSG) and was also responsible for increasing
significantly the level of lipid peroxides in the cells
(McCann et al. 2000). Furthermore, it was found (Pan-
imon et al. 1941) that whereas brain, kidney, liver
and muscle brei oxygen consumption is accelerated
by phen and its Fe(II) complex, [Fe(phen)3]2+, the
related Co(II)-, Ni(II)- and Cu(II)-phen complexes
produced no rate increase. No CO2 was formed dur-
ing the oxygen-uptake in the presence of phen and
[Fe(phen)3]2+ and it was thought that the compounds
were acting by catalysing the oxidation of either phos-
pholipids or proteins. Other workers (Moussa et al.
1990) have also reported enhanced respiration when
C. albicans is grown in the presence of either cisplatin
or palladium complexes and with the effect being at-
tributed to uncoupling of oxidative phosphorylation.
These various findings support the claim that the extra
oxygen taken up by the cells in the present experi-
ments is not being utilized for normal respiration but is
being used to induce oxidative stress in the organism.
Evidently, the yeasts own antioxidant enzymes (e.g.,
the copper-zinc andmanganese superoxide dismutases
and the catalases) are being overwhelmed by the drug
and are unable to offer any significant protection to the
organism (Hye-Jin et al. 1999).
Cytochromes play a central role in cellular respira-
tion, being integral parts of the electron transport chain
of oxidative phosphorylation. Certain cytochromes
(e.g., b and aa3) are composed of mitochondrial and
nuclear encoded material, so disruption of mitochon-
drial function results in a loss of cytochromes from
the respiratory chain and this can be visualized in a
differential spectrum (Whittaker & Danks 1978). The
data presented here indicate that the three metal-phen
complexes disrupt the synthesis of cytochromes b and
c in the yeast cells. In addition, the Ag(I) complex also
reduces the amount of cytochrome aa3 produced in the
cell. With uncomplexed phen cells exhibit lower levels
of b and c. However, with the increased absorption
beyond ca. 570 nm the effect on cytochrome aa3 is not
discernable.
The present complexes appear to be effective only
against actively respiring cells, suggesting that they
interfere with cytochrome synthesis but do not interact
to any great extent with fully intact cytochromes. In
the case of administering metal-free phen to cells in
the lag/exponential phase it is likely that the power-
fully chelating phen ligand is sequestering iron cations
from the reservoir of uncomplexed cellular iron and
thus making it unavailable for cytochrome synthe-
sis. The reduced activity of [Cu(phen)2(mal)] · 2H2O
and [Mn(phen)2(mal)] · 2H2O, compared to phen it-
self, can be attributed to the chemical structures of
the metal complexes. The X-ray crystal structures
of closely related Cu(II) (McCann et al. 1995) and
Mn(II) (Casey et al. 1995) dicarboxylate/phen com-
plexes shows the phen ligands to be strongly chelated
to the metal centers. As such, the equilibrium concen-
tration of uncomplexed phen arising from the incorpo-
ration of the Cu(II) and Mn(II) complexes inside cells
is expected to be relatively low, thus minimizing the
extent of complexation of iron which was destined for
cytochrome synthesis. Although the exact chemical
structure of [Ag2(phen)3(mal)] · 2H2O is not known
the more pronounced impact of this Ag(I) complex on
cytochrome formation is most likely due to the weaker
interaction of the phen ligand with the Ag(I) centre.
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This would ensure a higher equilibrium concentration
of the metal-free phen and which, subsequently, could
be utilized for coordination to cellular iron.
Ergosterol is an essential component of the fun-
gal cell membrane and provides stability and rigidity.
This sterol is the target of the anti-fungal agent am-
photericin B, which acts by binding ergosterol and
forming a pore or aperture through which leakage of
cell components can occur (Abu Salah 1996). In ad-
dition, the azole class of anti-fungal drugs function
by targeting ergosterol biosynthesis thus leading to a
weakened membrane and the synthesis of toxic in-
termediates which contribute to cell death (Klepser
et al. 1997). The present drugs, with the excep-
tion of [Mn(phen)2(mal)] · 2H2O, all reduce the levels
of cellular ergosterol. As the biosynthesis of ergos-
terol is controlled by NADPH, which itself is gen-
erated in the mitochondria (Daum et al. 1998), it
can be concluded that the increased oxygen-uptake
seen with the present drugs is not leading to the pro-
duction of more NADPH but more probably to the
generation of toxic free radicals. The fact that the
two Mn(II) complexes, [Mn(phen)2(mal)] · 2H2O and
[Mn(phen)2(CH3CO2)2] · 4H2O, promote increased
levels of ergosterol in the cell again suggests that the
mode of action of the complexes depends upon the
particular metal ion used {Mn(II), Cu(II) or Ag(I)}.
Conclusions
When tested against C. albicans phen, [Cu(phen)2
(mal)] · 2H2O, [Mn(phen)2(mal)] · 2H2O and
[Ag2(phen)3(mal)] · 2H2O are strongly fungistatic at
1.25–5.0μg cm−3 in RPMI and show some fungicidal
activity in MM at 10 μg cm−3. Under these condi-
tions the drugs damage mitochondrial function and
uncoupled respiration. With the exception of the Ag(I)
complex, all of the drugs increase oxygen-uptake by
the cells which is likely diverted to the formation of
damaging oxygen free radicals. All of the drugs ap-
pear to inhibit cytochrome biosynthesis and, with the
exception of [Mn(phen)2(mal)] · 2H2O, also lead to a
decrease in cellular ergosterol content.
Thus, phen and its Cu(II), Mn(II) and Ag(I) com-
plexes represent a novel set of anti-fungal drugs with
a mode of action quite different to that of the poly-
ene and azole prescription drugs. That the drugs are
not uniformly active indicates a degree of metal-ion
dependency on their mode of action.
Acknowledgements
Barry Coyle acknowledges support from Enterprise
Ireland.
References
Abu Salah KM. 1996 Amphotericin B: an update. Brit J Biomed Sci
53, 122–133.
Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. 1999 Quan-
titation of ergosterol content: novel method for determination of
fluconazole susceptibility of Candida albicans. J Clin Microbiol
37, 3332–3337.
Casey MT, McCann M, Devereux M, Curran M, McKee V. 1995
Synthesis and catalase activity of manganese(II) complexes
of cis-5-norbornene-endo-2,3-dicarboxylic acid (ndaH2): X-ray
crystal structure of [Mn(nda)(phen)2 ] ·EtOH ·H2O (phen =
1,10-phenanthroline). Polyhedron 14, 2247–2253.
Daum G, Lees ND, Bard M, Dickson R. 1998 Biochemistry,
cell biology and molecular biology of lipids of Saccharomyces
cerevisiae. Yeast 14, 1471–1510.
Dening DW, Evans EG, Kibbler CC. et al. 1997 Guidelines for the
investigation of invasive fungal infections in haematological ma-
lignancy and solid organ transplantation. Eur J Clin Microbiol
Infect Dis 16, 424–436.
Devereux M, McCann M, Leon V, Geraghty M, McKee V,
Wikaira J. 2000a Synthesis and fungitoxic activity of man-
ganese(II) complexes of fumaric acid: X-ray crystal structures of
[Mn(fum)(bipy)(H2O)] and [Mn(phen)2(H2O)2](fum) · 4H2O
(fumH2 = fumaric acid; bipy = 2,2′-bipyridine; phen = 1,10-
phenanthroline). Polyhedron 19, 1205–1211.
Devereux M, McCann M, Leon V, Geraghty M, McKee
V, Wikaira J. 2000b Synthesis and biological activity of
manganese(II) complexes of phthalic and isophthalic acid:
X-ray crystal structures of [Mn(ph)(Phen)2(H2O)] · 4H2O,
[Mn(Phen)2(H2O)2]2(Isoph)2(Phen) · 12H2O and [Mn(Isoph)
(bipy)]4 · 2.75bipy}n (phH2 = phthalic acid; Isoph = isoph-
thalic acid; Phen = 1,10-phenanthroline; bipy = 2,2-bipyridine).
Metal-Based Drugs 7, 275–288.
Geraghty M, McCann M, Devereux M, Cronin JF, Curran
M, McKee V. 1999a Synthesis and anti-Candida activity of
cobalt(II) complexes of benzene-1,2-dioxyacetic acid (bdoaH2).
X-ray crystal structures of [Co(bdoa)(H2O)3]3.5H2O and
{[Co(phen)3](bdoa)2}2 · 24H2O (phen = 1,10-phenanthroline).
Metal-Based Drugs 6, 41–48.
Geraghty M, Sheridan V, McCann M, Devereux M. 1999b
Synthesis and anti-Candida activity of copper(II) and
manganese(II) carboxylate complexes: X-ray crys-
tal structures of [Cu(sal)(bipy)] ·C2H5OH ·H2O and
[Cu(norb)(phen)2 ] · 6.5H2O (salH2 = salicylic acid; norbH2
= cis-5-norbornene-endo-2,3-dicarboxylic acid; bipy = 2,2′-
bipyridine; phen = 1,10-phenanthroline). Polyhedron 18,
2931–2939.
Geraghty M, McCann M, Devereux M, McKee V. 1999c Synthesis
and anti-Candida activity of cobalt(II) complexes of octanedioic
acid (odaH2) and nonanedioic acid (ndaH2): X-ray crystal struc-
tures of [Co(phen)3]oda · 14H2O and [Co(phen)3]nda · 11.5H2O
(phen = 1,10-phenanthroline). Inorg Chim Acta 293, 160–166.
Geraghty M, Cronim JF, Devereux M, McCann M. 2000 Synthesis
and antimicrobial activity of copper(II) and manganese(II) α,ω-
dicarboxylate complexes. BioMetals 13, 1–8.
329
Hye-Jin K, Byoung-Kuk N, Moon-Bo K. et al. 1999 Protective
effects of antioxidant enzymes of Candida albicans against
oxidative killing by macrophages. J Microbiol 117–122.
Klepser ME, Ernst EJ, Pfaller MA. 1997 Update on anti-fungal
resistance. Trends Microbiol 5, 372–375.
Lunel FMV, Meis J, Voss A. 1999 Nosocomial fungal infections.
Candidemia. Diagn Microbiol Infect Dis 34, 213–220.
McCann M, Cronin FJ, Devereux M. et al. 1995 Cop-
per(II) complexes of heptanedioic acid (hdaH2) and
octanedioic acid (odaH2): X-ray crystal structures of
[Cu(hda)(phen)2] · 11.73H2O and [Cu(oda)(phen)2] · 12H2)
(phen = 1,10-phenanthroline). Polyhedron 14, 2379–2387.
McCann M, Geraghty M, Devereux M. et al. 2000 Insights
into the mode of action of the anti-Candida activity of 1,10-
phenanthroline and its metal chelates. Metal-Based Drugs 7,
185–193.
Moran GP, Sanglard D, Donnelly SM, Shanley D, Sullivan DJ,
Colemen DC. 1998 Identification and expression of multi-drug
transporters responsible for fluconazole resistance in Candida
dubliniensis. Antimicrob Agent Chemother 42, 1819–1830.
Moussa NM, Ghannoum MA, Whittaker PA, El-Ezaby MS,
Quraman S. 1990 Effects of cisplatin and two novel palladium
complexes on Candida albicans, Microbios 62, 165–178.
Odds FC. 1996 Resistance of clinically important yeasts to antifun-
gal agents. Int J Antimicrob Agent 6, 145–147.
Panimon F, Horwitt MK, Gerard RW. 1941 Orthophenanthroline as
accelerator of brain tissue oxygen consumption. J Cell Comp
Physiol 17, 17–29.
Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. 1998
National surveillance of nosocomial blood stream infection due
to Candida albicans: frequency of occurrence and anti-fungal
susceptibility in the SCOPE program. Diagn Microbiol Infect Dis
31, 327–332.
Reeves E, Kavanagh K, Whitaker PA. 1991 Cupferron – a novel
petite inducing agent in yeast. Biomed Letts 46, 253–257.
Whittaker PA and Danks SM. 1978 Mitochondria: Structure, Func-
tion and Assembly. Integrated Themes in Biology. London:
Longman.
Wirsching S, Michel S, Kohler G, Morschhauser J. 2000 Activation
of the multiple drug resistance gene MDR1 in fluconazole resis-
tant clinical Candida albicans strains is caused by mutations in a
trans-regulatory factor. J Bacteriol 182, 400–404.
